(Q45219658)

English

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial

scientific article published on 5 November 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

phase II clinical trial

0 references

multicenter clinical trial

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

1

object named as

Pasi A Jänne

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

author name string

Sai-Hong I Ou

2

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Dong-Wan Kim

3

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Geoffrey R Oxnard

4

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Renato Martins

5

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Frank Dunphy

7

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Makoto Nishio

8

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Joseph O'Connell

9

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Cloud Paweletz

10

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Ian Taylor

11

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Hui Zhang

12

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Zelanna Goldberg

13

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Tony Mok

14

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

publication date

5 November 2014

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

13

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

1433-1441

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2814%2970461-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(14)70461-9

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45219658&oldid=2070425458"